Comparing Enzo Biochem (ENZ) & Its Rivals

Enzo Biochem (NYSE: ENZ) is one of 21 public companies in the “Medical laboratories” industry, but how does it compare to its competitors? We will compare Enzo Biochem to similar companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Enzo Biochem and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Enzo Biochem $107.80 million -$2.50 million -123.00
Enzo Biochem Competitors $1.13 billion $76.65 million 210.42

Enzo Biochem’s competitors have higher revenue and earnings than Enzo Biochem. Enzo Biochem is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Enzo Biochem has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Enzo Biochem’s competitors have a beta of 1.24, meaning that their average stock price is 24% more volatile than the S&P 500.

Profitability

This table compares Enzo Biochem and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enzo Biochem -1.38% -2.95% -2.42%
Enzo Biochem Competitors -118.64% -181.74% -42.76%

Analyst Recommendations

This is a summary of recent ratings for Enzo Biochem and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enzo Biochem 0 0 0 0 N/A
Enzo Biochem Competitors 109 458 535 18 2.41

As a group, “Medical laboratories” companies have a potential upside of 17.05%. Given Enzo Biochem’s competitors higher possible upside, analysts plainly believe Enzo Biochem has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

66.2% of Enzo Biochem shares are held by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are held by institutional investors. 8.9% of Enzo Biochem shares are held by company insiders. Comparatively, 18.4% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Enzo Biochem competitors beat Enzo Biochem on 5 of the 9 factors compared.

About Enzo Biochem

Enzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 29 patient service centers in New York and New Jersey; and a free standing ?STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nordson Co.  Stake Boosted by Swiss National Bank
Nordson Co. Stake Boosted by Swiss National Bank
Reviewing NTT DATA Corp/ADR  and Computer Task Group
Reviewing NTT DATA Corp/ADR and Computer Task Group
Head-To-Head Contrast: United Technologies  vs. TAT Technologies
Head-To-Head Contrast: United Technologies vs. TAT Technologies
Critical Survey: Mobileye  versus American Software
Critical Survey: Mobileye versus American Software
Five9 Inc  Expected to Announce Earnings of $0.04 Per Share
Five9 Inc Expected to Announce Earnings of $0.04 Per Share
Henry Schein Inc  Shares Sold by Tredje AP fonden
Henry Schein Inc Shares Sold by Tredje AP fonden


© 2006-2018 Ticker Report. Google+.